| Followers | 240 |
| Posts | 15516 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Friday, August 01, 2014 11:35:56 AM
BSB - that is an amazing number of shares you have invested. I only wish I had that much to invest :)
A couple of notes,
1. I'm no expert, but like Afford just noted, I'll bet the German approval has been missed by a lot of people. It came out in the news on one day, there was lots of hoopla, and then... silence. You'd have to be a regular on this board to know that silence isn't something to be disturbed about. And I suggest for many, it's been forgotten or it never hit their radar screen.
But... as Dok and others have pointed out, Germany will produce a viable revenue stream for NWBO that, when it is sorted out, will be noticed. I would think that would at least protect your/our share value from dropping to $3, and more than likely, ought to lift if out of the $6s.
I'm not sure how easy it would be for institutions to take a big position in NWBO. It might be difficult to acquire a large number of shares with so many low volume days. But I'm not an expert AT ALL on that count. Perhaps someone else on the board can explain how an institution would establish a large position.
Mapman noted that NWBO will file its 10Q on August 14. Perhaps they'll wrap up their German negotiations by then and we'll get a nice surprise.
Finally, in an effort to help you decide whether you truly are comfortable holding the position you are in, I'd ask you this. If you were unfortunate enough to be diagnosed with GBM, what would you do? If your doctor recommended that you follow SOC, would you? Is there another trial you'd prefer to get into? If your doctor recommended that you NOT race off to Germany for treatment - either with L or Dr. Nesselhut's perhaps similar vaccine, would you listen?
If you'd listen to your doctor, then perhaps you should lighten your load. If you know you'd be on a plane to Germany or Israel to access L, then perhaps you should trust your own DD here.
I mean, if you'd trust your life to L, then perhaps you can trust parking so much money here. :)
A couple of notes,
1. I'm no expert, but like Afford just noted, I'll bet the German approval has been missed by a lot of people. It came out in the news on one day, there was lots of hoopla, and then... silence. You'd have to be a regular on this board to know that silence isn't something to be disturbed about. And I suggest for many, it's been forgotten or it never hit their radar screen.
But... as Dok and others have pointed out, Germany will produce a viable revenue stream for NWBO that, when it is sorted out, will be noticed. I would think that would at least protect your/our share value from dropping to $3, and more than likely, ought to lift if out of the $6s.
I'm not sure how easy it would be for institutions to take a big position in NWBO. It might be difficult to acquire a large number of shares with so many low volume days. But I'm not an expert AT ALL on that count. Perhaps someone else on the board can explain how an institution would establish a large position.
Mapman noted that NWBO will file its 10Q on August 14. Perhaps they'll wrap up their German negotiations by then and we'll get a nice surprise.
Finally, in an effort to help you decide whether you truly are comfortable holding the position you are in, I'd ask you this. If you were unfortunate enough to be diagnosed with GBM, what would you do? If your doctor recommended that you follow SOC, would you? Is there another trial you'd prefer to get into? If your doctor recommended that you NOT race off to Germany for treatment - either with L or Dr. Nesselhut's perhaps similar vaccine, would you listen?
If you'd listen to your doctor, then perhaps you should lighten your load. If you know you'd be on a plane to Germany or Israel to access L, then perhaps you should trust your own DD here.
I mean, if you'd trust your life to L, then perhaps you can trust parking so much money here. :)
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
